Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept effect on microglial activation in amyloid PET-positive MCI due to Alzheimer's disease
2015-002145-63Phase 2Terminated
- Sponsor
- University of Southampton
- Start
- Mar 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of etanercept in Alzheimer's disease (AD), mild cognitive impairment due to Alzheimer's disease, sponsored by University of Southampton. Started Mar 2016; status: terminated.
02
Drugs
etanercept
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2015-002145-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002145-63.